Ignite Creation Date:
2025-12-24 @ 12:57 PM
Ignite Modification Date:
2025-12-29 @ 2:28 AM
Study NCT ID:
NCT01634061
Status:
COMPLETED
Last Update Posted:
2020-12-09
First Post:
2012-06-26
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2012-09
Start Date Type:
None
Primary Completion Date:
2015-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2015-07
Completion Date Type:
ACTUAL
First Submit Date:
2012-06-26
First Submit QC Date:
None
Study First Post Date:
2012-07-06
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-12-06
Last Update Post Date:
2020-12-09
Last Update Post Date Type:
ACTUAL